Allianz Asset Management GmbH Has $101.72 Million Holdings in Exelixis, Inc. $EXEL

Posted by ABMN Staff on Feb 4th, 2026

Allianz Asset Management GmbH lifted its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 153.3% during the third quarter, HoldingsChannel.com reports. The firm owned 2,462,948 shares of the biotechnology company’s stock after purchasing an additional 1,490,520 shares during the period. Allianz Asset Management GmbH’s holdings in Exelixis were worth $101,720,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Norges Bank bought a new stake in Exelixis during the 2nd quarter worth about $122,099,000. Qube Research & Technologies Ltd increased its position in shares of Exelixis by 120.5% in the second quarter. Qube Research & Technologies Ltd now owns 3,047,222 shares of the biotechnology company’s stock valued at $134,306,000 after acquiring an additional 1,665,110 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in Exelixis by 42.9% during the second quarter. Arrowstreet Capital Limited Partnership now owns 5,262,643 shares of the biotechnology company’s stock worth $231,951,000 after acquiring an additional 1,580,567 shares in the last quarter. Prudential Financial Inc. boosted its position in Exelixis by 776.8% during the second quarter. Prudential Financial Inc. now owns 1,468,865 shares of the biotechnology company’s stock valued at $64,740,000 after purchasing an additional 1,301,330 shares during the last quarter. Finally, Bank of America Corp DE grew its stake in Exelixis by 38.2% in the second quarter. Bank of America Corp DE now owns 2,638,666 shares of the biotechnology company’s stock valued at $116,299,000 after purchasing an additional 728,956 shares in the last quarter. Institutional investors own 85.27% of the company’s stock.

Exelixis Stock Performance

Shares of EXEL stock opened at $42.59 on Wednesday. Exelixis, Inc. has a 52 week low of $32.38 and a 52 week high of $49.62. The company has a market capitalization of $11.42 billion, a price-to-earnings ratio of 17.97, a PEG ratio of 0.77 and a beta of 0.42. The company has a 50-day simple moving average of $43.76 and a 200 day simple moving average of $40.98.

Exelixis (NASDAQ:EXEL – Get Free Report) last released its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.10. Exelixis had a net margin of 29.63% and a return on equity of 31.06%. The firm had revenue of $597.76 million for the quarter, compared to analysts’ expectations of $590.04 million. During the same period in the prior year, the firm earned $0.47 EPS. The business’s revenue was up 10.8% on a year-over-year basis. Sell-side analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Barclays upped their price objective on Exelixis from $40.00 to $41.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 5th. Oppenheimer reaffirmed a “market perform” rating and set a $36.00 price target on shares of Exelixis in a research report on Wednesday, November 5th. TD Cowen reaffirmed a “buy” rating on shares of Exelixis in a research report on Wednesday, November 5th. Weiss Ratings reissued a “buy (b)” rating on shares of Exelixis in a research report on Thursday, January 22nd. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $45.00 target price on shares of Exelixis in a report on Tuesday, October 21st. Eleven investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Exelixis currently has an average rating of “Hold” and a consensus target price of $46.00.

Read Our Latest Research Report on EXEL

Insider Transactions at Exelixis

In other Exelixis news, Director Stelios Papadopoulos sold 100,000 shares of the company’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $43.55, for a total value of $4,355,000.00. Following the transaction, the director directly owned 1,189,228 shares of the company’s stock, valued at $51,790,879.40. This represents a 7.76% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Dana Aftab sold 48,383 shares of Exelixis stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $42.50, for a total value of $2,056,277.50. Following the sale, the executive vice president directly owned 664,778 shares of the company’s stock, valued at $28,253,065. This represents a 6.78% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 245,235 shares of company stock worth $10,490,600 in the last ninety days. 2.85% of the stock is currently owned by company insiders.

Exelixis News Summary

Here are the key news stories impacting Exelixis this week:

Positive Sentiment: U.S. FDA accepted the New Drug Application for zanzalintinib in combination with an immune checkpoint inhibitor for metastatic colorectal cancer — a regulatory acceptance increases the probability of future commercial upside if approved. Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib
Positive Sentiment: H.C. Wainwright reiterated a Buy rating and set a $52 price target (roughly ~22% above current levels), citing multi-tumor commercial potential for zanzalintinib — analyst backing can support upward price pressure. Exelixis: Advancing Zanzalintinib Pipeline Underpins Buy Rating and $52 Target
Positive Sentiment: Zacks highlights Exelixis as a strong momentum stock based on style scores — momentum interest can attract short-term buyers and algos. Here’s Why Exelixis (EXEL) is a Strong Momentum Stock
Neutral Sentiment: Zacks and other outlets are debating whether Exelixis still represents value after multiyear gains — useful for longer-term investors but less likely to move near-term price. Is It Too Late To Consider Exelixis (EXEL) After Strong Multi Year Share Gains?
Neutral Sentiment: Reported short-interest data show zero or erroneous values (likely a data glitch), so there’s no clear short-pressure signal from the report. Benzinga (short interest summary)
Negative Sentiment: Zacks flags that Exelixis may lack the setup for an earnings beat in the upcoming report — lowered beat odds or cautious guidance could weigh on the stock around the release. Exelixis (EXEL) Reports Next Week: Wall Street Expects Earnings Growth

About Exelixis

(Free Report)

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.